Nanocarriers for tracking and treating diseases

Current Medicinal Chemistry

Volumn 20, Issue 28, 2013, Pages 3500-3514

  Marrache, Sean ^a   Pathak, Rakesh Kumar ^a   Darley, Kasey L ^a   Choi, Joshua H ^a   Zaver, Dhillon ^a   Kolishetti, Nagesh ^a   Dhar, Shanta ^a  

^a UNIVERSITY OF GEORGIA   (United States)

Author keywords

Active targeting; Biomaterials; Blood brain barrier; Cancer; Cardiovascular diseases; Liposome; Nanomedicine; Nanotechnology; Neurodegenerative diseases; Passive targeting; Polymer

Indexed keywords

BIND 014; CALAA 01; CARBOPLATIN; CISPLATIN; CPX 1; CRLX 101; DAUNORUBICIN; DOXORUBICIN; FIRTECAN; LIPOSOME; MBP 426; MITOPODOZIDE; NANOCARRIER; NC 6004; NK 105; OXALIPLATIN; PACLITAXEL; SEL 068; SGT 53; SGT 94; UNCLASSIFIED DRUG; VINCRISTINE SULFATE;

ALZHEIMER DISEASE; CANCER DIAGNOSIS; CARDIOVASCULAR DISEASE; DISEASES; DRUG DELIVERY SYSTEM; ENCAPSULATION; HUMAN; LIPID BILAYER; PHYSICAL CHEMISTRY; POLYMERIZATION; REVIEW;

EID: 84883215550     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867311320280007     Document Type: Review

References (136)

1. Freitas, R. A. Jr. What is nanomedicine? Nanomed. Nanotechnol., 2005, 1(1), 2-9.
2. Farokhzad, O. C.; Langer, R. Impact of nanotechnology on drug delivery. ACS Nano, 2009, 3(1), 16-20.
3. Shi, J.; Votruba, A. R.; Farokhzad, O. C.; Langer, R. Nanotechnology in drug delivery and tissue engineering: from discovery to applications. Nano Lett., 2010, 10(9), 3223-3230.
4. Kamaly, N.; Xiao, Z.; Valencia, P. M.; Radovic-Moreno, A. F.; Farokhzad, O. C. Targeted polymeric therapeutic nanoparticles: design, development and clinical translation. Chem. Soc. Rev., 2012, 41(7), 2971-3010.
5. Soppimath, K. S.; Aminabhavi, T. M.; Kulkarni, A. R.; Rudzinski, W. E. Biodegradable polymeric nanoparticles as drug delivery devices. J. Control Release, 2001, 70(1-2), 1-20.
6. Wissing, S. A.; Kayser, O.; Muller, R. H. Solid lipid nanoparticles for parenteral drug delivery. Adv. Drug Deliv. Rev., 2004, 56(9), 1257-1272.
7. Marks, S. Liposome battle for antifungal market shifts into high gear. J. Int. Assoc. Physicians AIDS Care, 1996, 2(4), 46-47.
8. Ventola, C. L. The nanomedicine revolution: part 2: current and future clinical applications. P T., 2012, 37(10), 582-591.
9. Maeda, H. Tumor-selective delivery of macromolecular drugs via the EPR effect: background and future prospects. Bioconjugate Chem., 2010, 21(5), 797-802.
10. Matsumura, Y.; Maeda, H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res., 1986, 46(12), 6387-6392.
11. Leserman, L. D.; Barbet, J.; Kourilsky, F.; Weinstein, J. N. Targeting to cells of fluorescent liposomes covalently coupled with monoclonal antibody or protein A. Nature, 1980, 288(5791), 602-604.
12. Torchilin, V. P. Recent advances with liposomes as pharmaceutical carriers. Nat. Rev. Drug Discov., 2005, 4(2), 145-160.
13. Oku, N.; Namba, Y. Long-circulating liposomes. Crit. Rev. Ther. Drug, 1994, 11(4), 231-270.
14. Folkman, J.; Long, D. M. The use of silicone rubber as a carrier for prolonged drug therapy. J. Surg. Res., 1964, 4, 139-142.
15. Langer, R.; Folkman, J. Polymers for the sustained release of proteins and other macromolecules. Nature, 1976, 263(5580), 797-800.
16. Langer, R. Drug delivery. Drugs on target. Science, 2001, 293(5527), 58-59.
17. Richards Grayson, A. C.; Choi, I. S.; Tyler, B. M.; Wang, P. P.; Brem, H.; Cima, M. J.; Langer, R. Multi-pulse drug delivery from a resorbable polymeric microchip device. Nat. Mater., 2003, 2(11), 767-772.
18. Marrache, S.; Dhar, S. Engineering of blended nanoparticle platform for delivery of mitochondria-acting therapeutics. Proc. Natl. Acad. Sci. USA, 2012, 109(40), 16288-16293.
19. Alexis, F.; Basto, P.; Levy-Nissenbaum, E.; Radovic-Moreno, A. F.; Zhang, L.; Pridgen, E.; Wang, A. Z.; Marein, S. L.; Westerhof, K.; Molnar, L. K.; Farokhzad, O. C. HER-2-targeted nanoparticleaffibody bioconjugates for cancer therapy. Chem. Med. Chem., 2008, 3, 1839-1843.
20. Alexis, F.; Pridgen, E.; Molnar, L. K.; Farokhzad, O. C. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol. Pharmaceut., 2008, 5(4), 505-515.
21. Marrache, S.; Dhar, S. Biodegradable synthetic high-density lipoprotein nanoparticles for atherosclerosis. Proc. Natl. Acad. Sci. USA, 2013, 110(23), 9445-9450.
22. Chan, J. M.; Zhang, L.; Yuet, K. P.; Liao, G.; Rhee, J. W.; Langer, R.; Farokhzad, O. C. PLGA-lecithin-PEG core-shell nanoparticles for controlled drug delivery. Biomaterials, 2009, 30(8), 1627-1634.
23. Cheng, J.; Teply, B. A.; Sherifi, I.; Sung, J.; Luther, G.; Gu, F. X.; Levy-Nissenbaum, E.; Radovic-Moreno, A. F.; Langer, R.; Farokhzad, O. C. Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery. Biomaterials, 2007, 28(5), 869-876.
24. Cheng, J.; Teply, B. A.; Sherifi, I.; Sung, J.; Luther, G.; Gu, F. X.; Levy-Nissenbaum, E.; Radovic-Moreno, A. F.; Langer, R.; Farokhzad, O. C. Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery. Biomaterials, 2008, 28, 868-876.
25. Dhar, S.; Gu, F. X.; Langer, R.; Farokhzad, O. C.; Lippard, S. J. Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles. Proc. Natl. Acad. Sci. USA, 2008, 105(45), 17356-17361.
26. Dhar, S.; Kolishetti, N.; Lippard, S. J.; Farokhzad, O. C. Targeted delivery of a cisplatin prodrug for safer and more effective prostate cancer therapy in vivo. Proc. Natl. Acad. Sci. USA, 2011, 108(5), 1850-1855.
27. Farokhzad, O. C.; Jon, S. Y.; Khadelmhosseini, A.; Tran, T. N. T.; LaVan, D. A.; Langer, R. Nanopartide-aptamer bioconjugates: A new approach for targeting prostate cancer cells. Cancer Res., 2004, 64(21), 7668-7672.
28. Gu, F.; Zhang, L.; Teply, B. A.; Mann, N.; Wang, A.; Radovic-Moreno, A. F.; Langer, R.; Farokhzad, O. C. Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers. Proc. Natl. Acad. Sci. USA, 2008, 105(7), 2586-2591.
29. Hrkach, J.; Von Hoff, D.; Mukkaram Ali, M.; Andrianova, E.; Auer, J.; Campbell, T.; De Witt, D.; Figa, M.; Figueiredo, M.; Horhota, A.; Low, S.; McDonnell, K.; Peeke, E.; Retnarajan, B.; Sabnis, A.; Schnipper, E.; Song, J. J.; Song, Y. H.; Summa, J.; Tompsett, D.; Troiano, G.; Van Geen Hoven, T.; Wright, J.; LoRusso, P.; Kantoff, P. W.; Bander, N. H.; Sweeney, C.; Farokhzad, O. C.; Langer, R.; Zale, S. Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. Sci. Transl. Med., 2012, 4(128), 128ra139.
30. Kolishetti, N.; Dhar, S.; Valencia, P. M.; Lin, L. Q.; Karnik, R.; Lippard, S. J.; Langer, R.; Farokhzad, O. C. Engineering of selfassembled nanoparticle platform for precisely controlled combination drug therapy. Proc. Natl. Acad. Sci. USA, 2010, 107(42), 17939-17944.
31. Mamo, T.; Moseman, E. A.; Kolishetti, N.; Salvador-Morales, C.; Shi, J.; Kuritzkes, D. R.; Langer, R.; von Andrian, U.; Farokhzad, O. C. Emerging nanotechnology approaches for HIV/AIDS treatment and prevention. Nanomedicine-UK, 2010, 5(2), 269-285.
32. Wang, A. Z.; Gu, F.; Zhang, L.; Chan, J. M.; Radovic-Moreno, A.; Shaikh, M. R.; Farokhzad, O. C. Biofunctionalized targeted Nanoparticles for therapeurtic applications. Expert Opin. Biol. Th., 2008, 8(8), 1063-1070.
33. Zhang, L.; Chan, J. M.; Gu, F. X.; Rhee, J. W.; Wang, A. Z.; Radovic-Moreno, A. F.; Alexis, F.; Langer, R.; Farokhzad, O. C. Self-assembled lipid - polymer hybrid nanoparticles: a robust drug delivery platform. ACS Nano, 2008, 2(8), 1696-1702.
34. Zhang, L.; Radovic-Moreno, A. F.; Alexis, F.; Gu, F. X.; Basto, P. A.; Bagalkot, V.; Jon, S.; Langer, R. S.; Farokhzad, O. C. Co-delivery of hydrophobic and hydrophilic drugs from nanoparticleaptamer bioconjugates. ChemMedChem, 2007, 2(9), 1268-1271.
35. Kolishetti, N.; Alexis, F.; Pridgen, E. M.; Farokhzad, O. C., In: Nanoplatform-Based Molecular Imaging, John Wiley & Sons, Inc.; 2011; pp. 75-104.
36. Acharya, S.; Sahoo, S. K. PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect. Adv. Drug Deliv. Rev., 2011, 63(3), 170-183.
37. Knop, K.; Hoogenboom, R.; Fischer, D.; Schubert, U. S. Poly(ethylene glycol) in drug delivery: pros and cons as well as potential alternatives. Angew. Chem. Int. Ed., 2010, 49(36), 6288-6308.
38. Jokerst, J. V.; Lobovkina, T.; Zare, R. N.; Gambhir, S. S. Nanoparticle PEGylation for imaging and therapy. Nanomedicine-UK, 2011, 6(4), 715-728.
39. Davis, M. E.; Chen, Z. G.; Shin, D. M. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat. Rev. Drug Discov., 2008, 7(9), 771-782.
40. Lammers, T.; Kiessling, F.; Hennink, W. E.; Storm, G. Nanotheranostics and image-guided drug delivery: current concepts and future directions. Mol. Pharmaceut., 2010, 7(6), 1899-1912.
41. Jain, T. K.; Morales, M. A.; Sahoo, S. K.; Leslie-Pelecky, D. L.; Labhasetwar, V. Iron oxide nanoparticles for sustained delivery of anticancer agents. Mol. Pharmaceut., 2005, 2(3), 194-205.
42. Wassel, R. A.; Grady, B.; Kopke, R. D.; Dormer, K. J. Dispersion of super paramagnetic iron oxide nanoparticles in poly(d,l-lactideco-glycolide) microparticle. Colloids Surface A, 2007, 292, 125-130.
43. Rosi, N. L.; Mirkin, C. A. Nanostructures in biodiagnostics. Chem. Rev., 2005, 105, 1547-1562.
44. Katz, E.; Willner, I. Integrated nanoparticle-biomolecule hybrid systems: Synthesis, properties, and applications. Angew. Chem. Int. Ed., 2004, 43(45), 6042-6108.
45. Puri, A.; Blumenthal, R. Polymeric lipid assemblies as novel theranostic tools. Acc. Chem. Res., 2011, 44(10), 1071-1079.
46. Smith, A. M.; Dave, S.; Nie, S.; True, L.; Gao, X. Multicolor quantum dots for molecular diagnostics of cancer. Expert Rev. Mol. Diagn., 2006, 6(2), 231-244.
47. Morgan, B. Opportunities and pitfalls of cancer imaging in clinical trials. Nat. Rev. Clin. Oncol., 2011, 8(9), 517-527.
48. Kircher, M. F.; Mahmood, U.; King, R. S.; Weissleder, R.; Josephson, L. A multimodal nanoparticle for preoperative magnetic resonance imaging and intraoperative optical brain tumor delineation. Cancer Res., 2003, 63(23), 8122-8125.
49. Jokerst, J. V.; Gambhir, S. S. Molecular imaging with theranostic nanoparticles. Acc. Chem. Res., 2011, 44(10), 1050-1060.
50. Mulder, W. J.; Griffioen, A. W.; Strijkers, G. J.; Cormode, D. P.; Nicolay, K.; Fayad, Z. A. Magnetic and fluorescent nanoparticles for multimodality imaging. Nanomedicine-UK, 2007, 2(3), 307-324.
51. Mulder, W. J.; Strijkers, G. J.; van Tilborg, G. A.; Cormode, D. P.; Fayad, Z. A.; Nicolay, K. Nanoparticulate assemblies of amphiphiles and diagnostically active materials for multimodality imaging. Acc. Chem. Res., 2009, 42(7), 904-914.
52. Brannon-Peppas, L.; Blanchette, J. O. Nanoparticle and targeted systems for cancer therapy. Adv. Drug Deliv. Rev., 2004, 56(11), 1649-1659.
53. Jain, R. K. Transport of molecules, particles, and cells in solid tumors. Annu. Rev. Biomed. Eng., 1999, 1, 241-263.
54. Sokolov, K.; Follen, M.; Aaron, J.; Pavlova, I.; Malpica, A.; Lotan, R.; Richards-Kortum, R. Real-time vital optical imaging of precancer using anti-epidermal growth factor receptor antibodies conjugated to gold nanoparticles. Cancer Res., 2003, 63(9), 1999-2004.
55. Byrne, J. D.; Betancourt, T.; Brannon-Peppas, L. Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv. Drug Deliv. Rev., 2008, 60(15), 1615-1626.
56. Yanga, J.; Lima, E.-K.; Leeb, H. J.; Parka, J.; Leeb, S. C.; Leec, K.; Yoond, H.-G.; Suhe, J.-S.; Huhe, Y.-M.; Haama, S. Fluorescent magnetic nanohybrids as multimodal imaging agents for human epithelial cancer detection. Biomaterials, 2008, 29(16), 2548-2555.
57. Wagh, A.; Qian, S. Y.; Law, B. Development of biocompatible polymeric nanoparticles for in vivo NIR and FRET imaging. Bioconjugate Chem., 2012, 23, 981-992.
58. Ye, F. R.; Ke, T. Y.; Jeong, E. K.; Wang, X. L.; Sung, Y. G.; Johnson, M.; Lu, Z. R. Noninvasive visualization of in vivo drug delivery of poly(L-glutamic acid) using contrast-enhanced MRI. Mol. Pharmaceut., 2006, 3(5), 507-515.
59. Doiron, A. L.; Homan, K. A.; Emelianov, S.; Brannon, L. Poly(lactic-co-glycolic) acid as a carrier for imaging contrast agents. Pharma. Res., 2009, 26(3), 674-682.
60. Lloyd-Jones, D.; Adams, R. J.; Brown, T. M.; Carnethon, M.; Dai, S.; Simone, G. D.; Ferguson, T. B.; Ford, E.; Furie, K.; Gillespie, C.; Go, A.; Greenlund, K.; Haase, N.; Hailpern, S.; Ho, P. M.; Howard, V.; Kissela, B.; Kittner, S.; Lackland, D.; Lisabeth, L.; Marelli, A.; McDermott, M. M.; Meigs, J.; Mozaffarian, D.; Mussolino, M.; Nichol, G.; Roger, V. L.; Rosamond, W.; Sacco, R.; Sorlie, P.; Stafford, R.; Thom, T.; Wasserthiel-Smoller, S.; Wong, N. D.; Wylie-Rosett, J. Heart disease and stroke statistics - 2010 update: A report from the American Heart Association. Circulation, 2010, 121, 46-215.
61. Godin, B.; Sakamoto, J. H.; Serda, R. E.; Grattoni, A.; Bouamrani, A.; Ferrari, M. Emerging applications of nanomedicine for the diagnosis and treatment of cardiovascular diseases. Cell, 2010, 31(5), 199-205.
62. 33-intergrintargeted nanoparticles. Circulation, 2003, 108, 2270-2274.
63. Peters, D.; Kastantin, M.; Kotamraju, V. R.; Karmali, P. P.; Gujraty, K.; Tirrell, M.; Ruoslahti, E. Targeting atherosclerosis by using modular, multifunctional micelles. Proc. Natl. Acad. Sci. USA, 2009, 106(24), 9815-9819.
64. Pan, D.; Williams, T. A.; Senpan, A.; Allen, J. S.; Scott, M. J.; Gaffney, P. J.; Wickline, S. A.; Lanza, G. M. Detecting vascular biosignatures with a colloidal, radio-opaque polymeric nanoparticle. J. Am. Chem. Soc., 2009, 131(42), 15522-15527.
65. Nahrendorf, M.; Zhang, H.; Hembrador, S.; Panizzi, P.; Sosnovik, D. E.; Aikawa, E.; Libby, P.; Swirski, F. K.; Weissleder, R. Nanoparticle PET-CT imaging of macrophages in inflammatory atherosclerosis. Circulation, 2007, 117, 379-387.
66. Ross, C. A.; Poirier, M. A. Protein aggregation and neurodegenerative disease. Nat. Med., 2004, 10 Suppl, S10-17.
67. Patel, M. M.; Goyal, B. R.; Bhadada, S. V.; Bhatt, J. S.; Amin, A. F. Getting into the brain: Approaches to enhance brain drug delivery. CNS Drugs, 2009, 23(1), 35-58.
68. Re, F.; Moresco, R.; Masserini, M. Nanoparticles for neuroimaging. J. Phys. D Appl. Phys., 2012, 45(7), 073001/073001-073001/073012.
69. Kreuter, J. Nanoparticulate systems for brain delivery of drugs. Adv. Drug Deliv. Rev., 2001, 47(1), 65-81.
70. Kreuter, J.; Shamenkov, D.; Petrov, V.; Ramge, P.; Cychutek, K.; Koch-Brandt, C.; Alyautdin, R. Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier. J. Drug Target., 2002, 10(4), 317-325.
71. Popovic, N.; Brundin, P. Therapeutic potential of controlled drug delivery systems in neurodegenerative diseases. Int. J. Pharm., 2006, 314(2), 120-126.
72. Kreuter, J.; Alyautdin, R. N.; Kharkevich, D. A.; Ivanov, A. A. Passage of peptides through the blood-brain barrier with colloidal polymer particles (nanoparticles). Brain Res., 1995, 674(1), 171-174.
73. Koffie, R. M.; Farrar, C. T.; Saidi, L.-J.; William, C. M.; Hyman, B. T.; Spires-Jones, T. L. Nanoparticles enhance brain delivery of blood-brain barrier-impermeable probes for in vivo optical and magnetic resonance imaging. Proc. Natl. Acad. Sci. USA, 2011, 108(46), 18837-18842.
74. Menei, P.; Daniel, V.; Montero-Menei, C.; Brouillard, M.; Pouplard-Barthelaix, A.; Benoit, J. P. Biodegradation and brain tissue reaction to poly(D,L-lactide-co-glycolide) microspheres. Biomaterials, 1993, 14(6), 470-478.
75. Emerich, D. F.; Tracy, M. A.; Ward, K. L.; Figueiredo, M.; Qian, R.; Henschel, C.; Bartus, R. T. Biocompatibility of poly (DLlactide-co-glycolide) microspheres implanted into the brain. Cell Transplant., 1999, 8(1), 47-58.
76. Shi, N.; Pardridge, W. M. Noninvasive gene targeting to the brain. Proc. Natl. Acad. Sci. USA, 2000, 97(13), 7567-7572.
77. Shi, N.; Zhang, Y.; Zhu, C.; Boado, R. J.; Pardridge, W. M. Brainspecific expression of an exogenous gene after i.v. administration. Proc. Natl. Acad. Sci. USA, 2001, 98(22), 12754-12759.
78. Tosi, G.; Bondioli, L.; Ruozi, B.; Badiali, L.; Severini, G. M.; Biffi, S.; De Vita, A.; Bortot, B.; Dolcetta, D.; Forni, F.; Vandelli, M. A. NIR-labeled nanoparticles engineered for brain targeting: in vivo optical imaging application and fluorescent microscopy evidences. J. Neural Transm., 2011, 118(1), 145-153.
79. Nance, E. A.; Woodworth, G. F.; Sailor, K. A.; Shih, T. Y.; Xu, Q.; Swaminathan, G.; Xiang, D.; Eberhart, C.; Hanes, J. A dense poly(ethylene glycol) coating improves penetration of large polymeric nanoparticles within brain tissue. Sci. Transl. Med., 2012, 4(149), 149ra119.
80. Strebhardt, K.; Ullrich, A. Paul Ehrlich's magic bullet concept: 100 years of progress. Nat. Rev. Cancer, 2008, 8(6), 473-480.
81. Brigger, I.; Morizet, J.; Laudani, L.; Aubert, G.; Appel, M.; Velasco, V.; Terrier-Lacombe, M. J.; Desmaele, D.; d'Angelo, J.; Couvreur, P.; Vassal, G. Negative preclinical results with stealth nanospheres-encapsulated Doxorubicin in an orthotopic murine brain tumor model. J. Control. Release, 2004, 100(1), 29-40.
82. Jain, J. P.; Yenet Ayen, W.; Domb, A. J.; Kumar, N., In: Biodegradable Polymers in Clinical Use and Clinical Development, John Wiley & Sons, Inc.; Hoboken, NJ, USA, 2011; pp. 1-58.
83. Maeda, H.; Matsumura, Y. Tumoritropic and lymphotropic principles of macromolecular drugs. Crit. Rev. Ther. Drug, 1989, 6(3), 193-210.
84. Maeda, H.; Sawa, T.; Konno, T. Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS. J. Control. Release, 2001, 74(1-3), 47-61.
85. Yuan, F.; Dellian, M.; Fukumura, D.; Leunig, M.; Berk, D. A.; Torchilin, V. P.; Jain, R. K. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res., 1995, 55(17), 3752-3756.
86. Yuan, F.; Leunig, M.; Huang, S. K.; Berk, D. A.; Papahadjopoulos, D.; Jain, R. K. Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft. Cancer Res., 1994, 54(13), 3352-3356.
87. Kong, G.; Braun, R. D.; Dewhirst, M. W. Hyperthermia enables tumor-specific nanoparticle delivery: effect of particle size. Cancer Res., 2000, 60(16), 4440-4445.
88. Pun, S. H.; Tack, F.; Bellocq, N. C.; Cheng, J.; Grubbs, B. H.; Jensen, G. S.; Davis, M. E.; Brewster, M.; Janicot, M.; Janssens, B.; Floren, W.; Bakker, A. Targeted delivery of RNA-cleaving DNA enzyme (DNAzyme) to tumor tissue by transferrin-modified, cyclodextrin-based particles. Cancer Biol. Ther., 2004, 3(7), 641-650.
89. Pirollo, K. F.; Chang, E. H. Does a targeting ligand influence nanoparticle tumor localization or uptake? Trends Biotechnol., 2008, 26(10), 552-558.
90. Kirpotin, D. B.; Drummond, D. C.; Shao, Y.; Shalaby, M. R.; Hong, K.; Nielsen, U. B.; Marks, J. D.; Benz, C. C.; Park, J. W. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res., 2006, 66(13), 6732-6740.
91. Hussain, S.; Pluckthun, A.; Allen, T. M.; Zangemeister-Wittke, U. Antitumor activity of an epithelial cell adhesion molecule targeted nanovesicular drug delivery system. Mol. Cancer Ther., 2007, 6(11), 3019-3027.
92. Jain, R. K. Delivery of molecular and cellular medicine to solid tumors. Adv. Drug Deliv. Rev., 2001, 46(1-3), 149-168.
93. Verma, A.; Uzun, O.; Hu, Y.; Hu, Y.; Han, H. S.; Watson, N.; Chen, S.; Irvine, D. J.; Stellacci, F. Surface-structure-regulated cell-membrane penetration by monolayer-protected nanoparticles. Nat. Mater., 2008, 7(7), 588-595.
94. Gratton, S. E.; Ropp, P. A.; Pohlhaus, P. D.; Luft, J. C.; Madden, V. J.; Napier, M. E.; DeSimone, J. M. The effect of particle design on cellular internalization pathways. Proc. Natl. Acad. Sci. USA, 2008, 105(33), 11613-11618.
95. Barenholz, Y. Doxil(R) - the first FDA-approved nano-drug: lessons learned. J. Control. Release, 2012, 160(2), 117-134.
96. Esteva, F. J.; Valero, V.; Pusztai, L.; Boehnke-Michaud, L.; Buzdar, A. U.; Hortobagyi, G. N. Chemotherapy of metastatic breast cancer: what to expect in 2001 and beyond. Oncologist, 2001, 6(2), 133-146.
97. Koudelka, S.; Turanek, J. Liposomal paclitaxel formulations. J. Control. Release, 2012, 163(3), 322-334.
98. Gradishar, W. J. Albumin-bound paclitaxel: a next-generation taxane. Expert Opin. Pharmaco., 2006, 7(8), 1041-1053.
99. Rosenberg, B.; VanCamp, L.; Trosko, J. E.; Mansour, V. H. Platinum compounds: A new class of potent antitumour agents. Nature, 1969, 222(5191), 385-386.
100. Jamieson, E. R.; Lippard, S. J. Structure, recognition, and processing of cisplatin-DNA adducts. Chem. Rev., 1999, 99(9), 2467-2498.
101. Dhar, S.; Lippard, S., In: Platinum and Other Heavy Metal Compounds in Cancer Chemotherapy, Bonetti, A.; Leone, R.; Muggia, F.; Howell, S., Eds. Humana Press; 2009; pp. 135-147.
102. Dhar, S.; Lippard, S. J., In: Bioinorganic Medicinal Chemistry, Wiley-VCH Verlag GmbH & Co. KGaA; 2011; pp. 79-95.
103. Galanski, M.; Jakupec, M. A.; Keppler, B. K. Update of the preclinical situation of anticancer platinum complexes: novel design strategies and innovative analytical approaches. Curr. Med. Chem., 2005, 12(18), 2075-2094.
104. Avgoustakis, K.; Beletsi, A.; Panagi, Z.; Klepetsanis, P.; Karydas, A. G.; Ithakissios, D. S. PLGA-mPEG nanoparticles of cisplatin: in vitro nanoparticle degradation, in vitro drug release and in vivo drug residence in blood properties. J. Control. Release, 2002, 79(1-3), 123-135.
105. Fujiyama, J.; Nakase, Y.; Osaki, K.; Sakakura, C.; Yamagishi, H.; Hagiwara, A. Cisplatin incorporated in microspheres: development and fundamental studies for its clinical application. J. Control. Release, 2003, 89(3), 397-408.
106. Karve, S.; Werner, M. E.; Sukumar, R.; Cummings, N. D.; Copp, J. A.; Wang, E. C.; Li, C. X.; Sethi, M.; Chen, R. C.; Pacold, M. E.; Wang, A. Z. Revival of the abandoned therapeutic wortmannin by nanoparticle drug delivery. Proc. Natl. Acad. Sci. USA, 2012, 109(21), 8230-8235.
107. Orjuela, P.; Gonzalez, I.; Osorio, L. Combination therapy as a strategy to prevent antimalarial drug resistance. Biomedica, 2004, 24(4), 423-437.
108. de Gaetano Donati, K.; Rabagliati, R.; Iacoviello, L.; Cauda, R. HIV infection, HAART, and endothelial adhesion molecules: current perspectives. Lancet Infect. Dis., 2004, 4(4), 213-222.
109. Suarez-Pinzon, W. L.; Power, R. F.; Yan, Y.; Wasserfall, C.; Atkinson, M.; Rabinovitch, A. Combination therapy with glucagon-like peptide-1 and gastrin restores normoglycemia in diabetic NOD mice. Diabetes, 2008, 57(12), 3281-3288.
110. Jia, J.; Zhu, F.; Ma, X.; Cao, Z.; Li, Y.; Chen, Y. Z. Mechanisms of drug combinations: interaction and network perspectives. Nat. Rev. Drug Discov., 2009, 8(2), 111-128.
111. Aryal, S.; Hu, C. M. J.; Zhang, L. F. Polymeric nanoparticles with precise ratiometric control over drug loading for combination therapy. Mol. Pharmaceut., 2011, 8(4), 1401-1407.
112. Marrache, S.; Choi, J. H.; Tundup, S.; Zaver, D.; Harn, D. A.; Dhar, S. Immune stimulating photoactive hybrid nanoparticles for metastatic breast cancer. Integr. Biol., 2013, 5(1), 215-223.
113. Roger, V. L.; Go, A. S.; Lloyd-Jones, D. M.; Benjamin, E. J.; Berry, J. D.; Borden, W. B.; Bravata, D. M.; Dai, S.; Ford, E. S.; Fox, C. S.; Fullerton, H. J.; Gillespie, C.; Hailpern, S. M.; Heit, J. A.; Howard, V. J.; Kissela, B. M.; Kittner, S. J.; Lackland, D. T.; Lichtman, J. H.; Lisabeth, L. D.; Makuc, D. M.; Marcus, G. M.; Marelli, A.; Matchar, D. B.; Moy, C. S.; Mozaffarian, D.; Mussolino, M. E.; Nichol, G.; Paynter, N. P.; Soliman, E. Z.; Sorlie, P. D.; Sotoodehnia, N.; Turan, T. N.; Virani, S. S.; Wong, N. D.; Woo, D.; Turner, M. B.; American Heart Association Statistics, C.; Stroke Statistics, S. Heart disease and stroke statistics - 2012 update: a report from the American Heart Association. Circulation, 2012, 125(1), e2-e220.
114. Libby, P.; Theroux, P. Pathophysiology of coronary artery disease. Circulation, 2005, 111(25), 3481-3488.
115. Biana, G.; Jason, H. S.; Rita, E. S.; Alessandro, G.; Ali, B.; Mauro, F. Review: Emerging applications of nanomedicine for the diagnosis and treatment of cardiovascular diseases. Trends Pharmacol. Sci., 2010, 31, 199-205.
116. Kim, K. S.; Khang, G.; Lee, D. Application of nanomedicine in cardiovascular diseases and stroke. Curr. Pharma. Design, 2011, 17(18), 1825-1833.
117. Bauters, C.; Banos, J. L.; Van Belle, E.; Mc Fadden, E. P.; Lablanche, J. M.; Bertrand, M. E. Six-month angiographic outcome after successful repeat percutaneous intervention for in-stent restenosis. Circulation, 1998, 97(4), 318-321.
118. Ganaha, F.; Kao, E. Y.; Wong, H.; Elkins, C. J.; Lee, J.; Modanlou, S.; Rhee, C.; Kuo, M. D.; Yuksel, E.; Cifra, P. N.; Waugh, J. M.; Dake, M. D. Stent-based controlled release of intravascular angiostatin to limit plaque progression and in-stent restenosis. J. Vasc. Interv. Radiol., 2004, 15(6), 601-608.
119. Reimers, B.; Moussa, I.; Akiyama, T.; Tucci, G.; Ferraro, M.; Martini, G.; Blengino, S.; Di Mario, C.; Colombo, A. Long-term clinical follow-up after successful repeat percutaneous intervention for stent restenosis. J. Am. Coll. Cardiol., 1997, 30(1), 186-192.
120. Popma, J. J.; Califf, R. M.; Topol, E. J. Clinical trials of restenosis after coronary angioplasty. Circulation, 1991, 84(3), 1426-1436.
121. Bauters, C.; Isner, J. M. The biology of restenosis. Prog. Cardiovasc. Dis., 1997, 40(2), 107-116.
122. Chorny, M.; Fishbein, I.; Golomb, G. Drug delivery systems for the treatment of restenosis. Crit. Rev. Ther. Drug, 2000, 17(3), 249-284.
123. Bhargava, B.; Karthikeyan, G.; Abizaid, A. S.; Mehran, R. New approaches to preventing restenosis. BMJ, 2003, 327(7409), 274-279.
124. Klugherz, B. D.; Jones, P. L.; Cui, X.; Chen, W.; Meneveau, N. F.; DeFelice, S.; Connolly, J.; Wilensky, R. L.; Levy, R. J. Gene delivery from a DNA controlled-release stent in porcine coronary arteries. Nat. Biotechnol., 2000, 18(11), 1181-1184.
125. Perlstein, I.; Connolly, J. M.; Cui, X.; Song, C.; Li, Q.; Jones, P. L.; Lu, Z.; DeFelice, S.; Klugherz, B.; Wilensky, R.; Levy, R. J. DNA delivery from an intravascular stent with a denatured collagenpolylactic-polyglycolic acid-controlled release coating: mechanisms of enhanced transfection. Gene Ther., 2003, 10(17), 1420-1428.
126. Mei, L.; Sun, H.; Jin, X.; Zhu, D.; Sun, R.; Zhang, M.; Song, C. Modified paclitaxel-loaded nanoparticles for inhibition of hyperplasia in a rabbit arterial balloon injury model. Pharm Res, 2007, 24(5), 955-962.
127. Margolis, J.; McDonald, J.; Heuser, R.; Klinke, P.; Waksman, R.; Virmani, R.; Desai, N.; Hilton, D. Systemic nanoparticle paclitaxel (nab-paclitaxel) for in-stent restenosis I (SNAPIST-I): a first-inhuman safety and dose-finding study. Clin. Cardiol., 2007, 30(4), 165-170.
128. McDowell, G.; Slevin, M.; Krupinski, J. Nanotechnology for the treatment of coronary in stent restenosis: a clinical perspective. Vasc. Cell, 2011, 3(1), 8.
129. Patel, T.; Zhou, J.; Piepmeier, J. M.; Saltzman, W. M. Polymeric nanoparticles for drug delivery to the central nervous system. Adv. Drug Deliv. Rev., 2012, 64(7), 701-705.
130. Vauthier, C.; Labarre, D.; Ponchel, G. Design aspects of poly(alkylcyanoacrylate) nanoparticles for drug delivery. J. Drug Target., 2007, 15(10), 641-663.
131. Muller, R. H.; Lherm, C.; Herbort, J.; Couvreur, P. In vitro model for the degradation of alkylcyanoacrylate nanoparticles. Biomaterials, 1990, 11(8), 590-595.
132. Kattan, J.; Droz, J. P.; Couvreur, P.; Marino, J. P.; Boutan-Laroze, A.; Rougier, P.; Brault, P.; Vranckx, H.; Grognet, J. M.; Morge, X.; et al. Phase I clinical trial and pharmacokinetic evaluation of doxorubicin carried by polyisohexylcyanoacrylate nanoparticles. Invest. New Drugs, 1992, 10(3), 191-199.
133. Bazile, D. V.; Ropert, C.; Huve, P.; Verrecchia, T.; Marlard, M.; Frydman, A.; Veillard, M.; Spenlehauer, G. Body distribution of fully biodegradable [14C]-poly(lactic acid) nanoparticles coated with albumin after parenteral administration to rats. Biomaterials, 1992, 13(15), 1093-1102.
134. Moghimi, S. M.; Hunter, A. C.; Murray, J. C. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol. Rev., 2001, 53(2), 283-318.
135. Vinogradov, S. V.; Batrakova, E. V.; Kabanov, A. V. Nanogels for oligonucleotide delivery to the brain. Bioconjugate Chem., 2004, 15(1), 50-60.
136. Aktas, Y.; Yemisci, M.; Andrieux, K.; Gursoy, R. N.; Alonso, M. J.; Fernandez-Megia, E.; Novoa-Carballal, R.; Quinoa, E.; Riguera, R.; Sargon, M. F.; Celik, H. H.; Demir, A. S.; Hincal, A. A.; Dalkara, T.; Capan, Y.; Couvreur, P. Development and brain delivery of chitosan-PEG nanoparticles functionalized with the monoclonal antibody OX26. Bioconjugate Chem., 2005, 16(6), 1503-1511.